Security key
M96088105
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)
CUSIP: M96088105
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Ordinary Shares, par value NIS 0.01 per share
- Shares outstanding
- 48,684,257
- Total 13F shares
- 46,410,597
- Share change
- +2,673,753
- Total reported value
- $834,606,821
- Put/Call ratio
- 76%
- Price per share
- $17.98
- Number of holders
- 169
- Value change
- +$44,013,702
- Number of buys
- 77
- Number of sells
- 72
Report period
Q1 2026
Institutions
169
Top holders
10
URGN full security history
Previous quarter: Q4 2025
UroGen Pharma Ltd. SEC filings
UroGen Pharma Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M96088105
Recent filing periods:
Top shareholders of URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
2,562,901
|
$60,023,155 | — | 31 Dec 2025 | |
| TORONTO DOMINION BANK |
13D/G
|
The Toronto-Dominion Bank |
5.4%
|
2,616,714
|
$53,066,960 | +$6,375,626 | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.2%
from 13D/G
|
2,601,009
|
$60,915,631 | — | 31 Dec 2025 | |
| MENORA MIVTACHIM HOLDINGS LTD. |
13F
13D/G
|
Company |
5%
from 13D/G
|
1,152,531
|
$26,992,276 | — | 31 Dec 2025 | |
| Soleus Capital Master Fund, L.P. |
13D/G
|
— |
4.7%
|
2,185,000
|
$31,114,400 | -$1,993,600 | 30 Jun 2025 | |
| Paradigm Biocapital Advisors LP |
13F
13D/G
|
Company |
3.5%
from 13D/G
|
4,473,648
|
$104,772,836 | — | 31 Dec 2025 | |
| Adage Capital Management, L.P. |
13D/G
|
— |
2.8%
|
1,277,000
|
$13,740,520 | -$17,765,685 | 31 Mar 2025 | |
| Monograph Capital Holdings Advisors, LLC |
13D/G
|
Monograph Capital Partners I, L.P. |
1.8%
|
838,615
|
$8,503,556 | $0 | 05 Jun 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
9.3%
|
4,543,895
|
$106,418,021 | — | 31 Dec 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
4.5%
|
2,199,652
|
$51,515,850 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.6%
|
1,738,821
|
$40,723,188 | — | 31 Dec 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
3%
|
1,448,420
|
$33,921,996 | — | 31 Dec 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
2.8%
|
1,377,647
|
$32,264,000 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
2.8%
|
1,358,812
|
$31,823,425 | — | 31 Dec 2025 | |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND |
13F
|
Company |
2.3%
|
1,125,100
|
$26,349,842 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2%
|
962,624
|
$22,544,654 | — | 31 Dec 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.9%
|
941,378
|
$22,047,073 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.8%
|
875,487
|
$20,503,906 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.7%
|
807,421
|
$18,909,800 | — | 31 Dec 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
1.6%
|
781,620
|
$18,305,546 | — | 31 Dec 2025 | |
| Migdal Insurance & Financial Holdings Ltd. |
13F
|
Company |
1.6%
|
770,909
|
$18,055,000 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.5%
|
737,757
|
$17,278,269 | — | 31 Dec 2025 | |
| SUPERSTRING CAPITAL MANAGEMENT LP |
13F
|
Company |
1.5%
|
718,354
|
$16,823,851 | — | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.5%
|
717,347
|
$16,800,267 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.3%
|
618,952
|
$14,495,856 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.3%
|
616,606
|
$14,441,000 | — | 31 Dec 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
1.1%
|
513,303
|
$12,021,556 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
1%
|
500,726
|
$11,727,003 | — | 31 Dec 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1%
|
500,000
|
$11,710,000 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.98%
|
475,212
|
$11,129,464 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.94%
|
459,722
|
$10,766,689 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.9%
|
439,751
|
$10,298,969 | — | 31 Dec 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.89%
|
435,490
|
$10,199,176 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.75%
|
366,680
|
$8,587,645 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.72%
|
350,000
|
$8,197,000 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.62%
|
302,601
|
$7,086,916 | — | 31 Dec 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.58%
|
281,876
|
$6,601,536 | — | 31 Dec 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
0.55%
|
268,423
|
$6,286,467 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.5%
|
244,300
|
$5,721,506 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.5%
|
241,213
|
$5,649,208 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.49%
|
237,457
|
$5,561,243 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.48%
|
235,040
|
$5,504,637 | — | 31 Dec 2025 | |
| Atom Investors LP |
13F
|
Company |
0.48%
|
234,423
|
$5,490,187 | — | 31 Dec 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.44%
|
214,622
|
$5,026,447 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.35%
|
168,768
|
$3,952,547 | — | 31 Dec 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.33%
|
162,725
|
$3,811,020 | — | 31 Dec 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.33%
|
161,924
|
$3,792,260 | — | 31 Dec 2025 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.33%
|
160,412
|
$3,756,849 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.32%
|
153,413
|
$3,592,933 | — | 31 Dec 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.31%
|
150,000
|
$3,513,000 | — | 31 Dec 2025 |
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q1 2026
As of 31 Mar 2026,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
169 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
46,410,597 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, BlackRock, Inc., TORONTO DOMINION BANK, MORGAN STANLEY, Kynam Capital Management, LP, Jefferies Financial Group Inc., Paradigm Biocapital Advisors LP, ACORN CAPITAL ADVISORS, LLC, SG Americas Securities, LLC, and AMERICAN CENTURY COMPANIES INC.
This page lists
169
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
167
Q1 2026 holders
169
Holder diff
2
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.